Fig. S1 Article selection flowchart

Table S1 Overview of studies included in the meta-analysis review

IDa / Study design / Location / Study period / Population / Sample (n) / Sex / Regimen / Age range / Follow-up (days/months) / Viral species / Diagnostic method
2 / prospective cohort / United States / 1993-1994 / human / 58 / Female (60%) / intravenous via
30 mg/Kg [≤2g], further 15 mg/Kg 4 times/day, 4 days
7.5 mg/Kg 4 times/day, 6 days / >12 (years) / 32 days / SNc, BCCd and Bayou / ELISA, RT-PCR, immunohisto-chemical
11 / randomized controlled trial / United States / 1996-2001 / human / 23 / Female (61%) / intravenous via
33 mg/Kg [≤2g], further 16mg/Kg [≤1g] 4 times/day, 4 days
8 mg/Kg [≤500 mg] 3 times/day, 3 days
Placebo for 7 days / 23-58 (years) / 6 months / SN / Western blot
14 / prospective cohort / Unites States / - / animal / 16 / Female (100%) / intravenous via (50, 100 mg/Kg/day), days 6, 8, 10, 12, and 14 post-infection / 6-8 week / ~35 days / Andes / ELISA, immunohisto-chemical
15 / prospective cohort / United States / - / animal / 27 / Female (100%) / intraperitoneal injection
(100, 50, 25, or 5 mg Kg-1 day-1 or PBS alone), 10 days / 28-42 (days) / 35 days / Andes / ELISA, RT-PCR, Western blot
3 / randomized controlled trial / United States / 2008 / animal / 50 / Ub / intraperitoneal injection
(12.5, 50, 100 mg/Kg) 15 days / U / 15 days / Hantaan / ELISA, real time RT-PCR
5 / randomized controlled trial / South Korea / 1985 / animal / 90 / U / intraperitoneal injection
(0, 5, 15 ,25 or 50 mg/Kg) 1 times/day, 14 days
(25, 50, 75 or 100 mg/Kg) 1 times/day, 14 days / U / 75 days / Hantaan / Immunofluor-escence
6 / randomized controlled trial / China / 1985-1987 / human / 242 / Male (73%) / intravenous via
33 mg/Kg followed by a dose of 16 mg/Kg 4 times/day, 4 days
8 mg/Kg 3 times/day, 3 days
Placebo treated received phosphate buffer. / 14-62 (years) / 3 years / Hantaan / ELISA